ACIUAC Immune SA

Nasdaq acimmune.com


$ 4.00 $ -0.14 (-3.37 %)    

Tuesday, 25-Jun-2024 15:59:56 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 4.01
$ 4.34
$ 4.00 x 105
$ 0.00 x 0
$ 3.97 - $ 4.34
$ 1.92 - $ 5.14
203,386
na
397.78M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-initiates-coverage-on-ac-immune-with-buy-rating-announces-price-target-of-8

BTIG analyst Thomas Shrader initiates coverage on AC Immune (NASDAQ:ACIU) with a Buy rating and announces Price Target of $8.

 why-is-small-cap-alzheimers-focused-ac-immune-stock-trading-higher-on-monday

Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potenti...

Core News & Articles
Market-Moving News for May 13th
05/13/2024 12:42:15

GME: 46% | GameStop shares are trading higher amid possible retail investor interest following a social media post by Roaring K...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-received-decision-to-grant-european-patent-ep3735411-1345-tetrahydro-2h-pyrido43-bindole-derivatives-for-the-treatment-alleviation-or-prevention-of-disorders-associated-with-tau-aggregates-like-alzheimers-disease

https://register.epo.org/application?number=EP21153153

 ac-immune-raises-50m-its-alzheimers-targeting-immunotherapy-advances-into-phase-2b-trial

AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35...